Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 14 (Search time: 0.009 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2015Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AMLForristal, C.; Brown, A.; Helwani, F.; Winkler, I.; Nowlan, B.; Barbier, V.; Powell, R.; Engler, G.; Diakiw, S.; Zannettino, A.; Martin, S.; Pattabiraman, D.; D'Andrea, R.; Lewis, I.; Levesque, J.
2015Brief report: The differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiationMartin, S.; Fitter, S.; Dutta, A.; Matthews, M.; Walkley, C.; Hall, M.; Ruegg, M.; Gronthos, S.; Zannettino, A.
2018mTORC1 plays an important role in osteoblastic regulation of B-lymphopoiesisMartin, S.; Fitter, S.; El Khawanky, N.; Grose, R.; Walkley, C.; Purton, L.; Ruegg, M.; Hall, M.; Gronthos, S.; Zannettino, A.
2017HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1Vandyke, K.; Zeissig, M.; Hewett, D.; Martin, S.; Mrozik, K.; Cheong, C.; Diamond, P.; To, L.; Gronthos, S.; Peet, D.; Croucher, P.; Zannettino, A.
2011The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myelomaMartin, S.; Diamond, P.; Gronthos, S.; Peet, D.; Zannettino, A.
2010NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cellsMartin, S.; Fitter, S.; Bong, L.; Drew, J.; Gronthos, S.; Shepherd, P.; Zannettino, A.
2010Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patientsWilliams, S.; Martin, S.; Vincent, C.; Gronthos, S.; Zheng, T.; Atkins, G.; Zannettino, A.
2017mTORC1 plays an important role in skeletal development by controlling preosteoblast differentiationFitter, S.; Matthews, M.; Martin, S.; Xie, J.; Ooi, S.; Walkley, C.; Codrington, J.; Ruegg, M.; Hall, M.; Proud, C.; Gronthos, S.; Zannettino, A.
2004Angiogenesis in multiple myeloma: Implications in myeloma therapyMartin, S.; To, L.; Horvath, N.; Zannettino, A.
2015The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myelomaMartin, S.; Gan, Z.; Fitter, S.; To, L.; Zannettino, A.